We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$2B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
+25.15%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$36.5M
(+5.2%)
Cap. Flow
-$61.8M
Cap. Flow
% of AUM
-8.41%
Top 10 Holdings %
Top 10 Hldgs %
51.18%
Holding
61
New
18
Increased
7
Reduced
18
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$19.1M |
| 2 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$17.3M |
| 3 |
MRSN
Mersana Therapeutics
MRSN
|
+$16.4M |
| 4 |
Annexon
ANNX
|
+$15.3M |
| 5 |
Cytokinetics
CYTK
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IDEAYA Biosciences
IDYA
|
+$38M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$37M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$24.8M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$16.1M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$15.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $56.9M | 7.74% |
625,000
-175,000
| -22% | -$15.1M |
|
|
2
Cytokinetics
CYTK
$11B
| $53.8M | 7.32% |
1,650,000
+400,000
| +32% | +$14.8M |
|
3
Immunovant
IMVT
$8.24B
| $42.7M | 5.81% |
2,250,000
-250,000
| -10% | -$4.66M |
|
|
4
IDEAYA Biosciences
IDYA
$3.46B
| $41.1M | 5.59% |
1,750,000
-1,850,000
| -51% | -$38M |
|
5
Sarepta Therapeutics
SRPT
$1.72B
| $34.4M | 4.67% |
300,000
+80,000
| +36% | +$10.3M |
|
6
Olema Pharmaceuticals
OLMA
$1.08B
| $33.8M | 4.6% |
3,743,875
| – | – |
|
7
Immunocore
IMCR
$1.76B
| $30M | 4.08% |
500,000
| – | – |
|
8
Biogen
BIIB
$29.7B
| $28.5M | 3.87% |
100,000
| – | – |
|
9
Neurocrine Biosciences
NBIX
$17.8B
| $28.3M | 3.85% |
300,000
+100,000
| +50% | +$9.77M |
|
10
Viridian Therapeutics
VRDN
$2.19B
| $26.8M | 3.64% |
1,125,000
+175,000
| +18% | +$4.49M |
|
|
AKRO
11
DELISTED
Akero Therapeutics
AKRO
| $24.3M | 3.3% |
520,000
+120,000
| +30% | +$5.5M |
|
|
ALLK
12
DELISTED
Allakos
ALLK
| $22.9M | 3.11% |
5,250,000
-286,666
| -5% | -$1.29M |
|
|
ICVX
13
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $21.5M | 2.93% |
+2,165,741
| New | +$17.3M |
|
14
Dyne Therapeutics
DYN
$4.16B
| $20M | 2.72% |
1,780,000
+80,000
| +5% | +$944K |
|
15
Design Therapeutics
DSGN
$747M
| $17.6M | 2.4% |
2,797,501
| – | – |
|
16
Structure Therapeutics
GPCR
$3.49B
| $16.6M | 2.26% |
400,000
+50,000
| +14% | +$1.4M |
|
|
ACLX
17
DELISTED
Arcellx
ACLX
| $15.8M | 2.15% |
+500,000
| New | +$19.1M |
|
18
Arcus Biosciences
RCUS
$3.53B
| $15.2M | 2.07% |
+750,000
| New | +$14.3M |
|
|
BCYC
19
Bicycle Therapeutics
BCYC
$279M
| $13.3M | 1.81% |
520,000
-230,000
| -31% | -$5.34M |
|
|
20
Annexon
ANNX
$873M
| $12.3M | 1.68% |
+3,500,000
| New | +$15.3M |
|
21
CALL
BridgeBio Pharma
BBIO
$16.5B
| $11.2M | 1.52% |
+650,000
| New | +$9.78M |
|
|
22
Xenon Pharmaceuticals
XENE
$6.32B
| $10.6M | 1.44% |
275,000
-625,000
| -69% | -$24.8M |
|
|
LKFT
23
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
| $10.2M | 1.38% |
250,000
-100,000
| -29% | -$4.08M |
|
24
Cogent Biosciences
COGT
$6.89B
| $9.47M | 1.29% |
800,000
-200,000
| -20% | -$2.29M |
|
|
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
| $9.21M | 1.25% |
+112,000
| New | +$16.4M |
|
Similar funds
MYAM
RCM
LBC
C
CAM
BGM
SC
AF
Logos Global Management's Q2 2023 Portfolio in Review
As of Q2 2023, Logos Global Management held 61 positions worth $735M, up 5.2% from $699M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Logos Global Management withdrew a net $61.8M in Q2 2023, closing 10 positions and reducing 18 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $37M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.
Against the trend, Logos Global Management opened a new position in Arcellx worth $15.8M.
- Logos Global Management's largest Q2 2023 buy was Arcellx: 500,000 shares worth $15.8M.
- Logos Global Management added most to Cytokinetics in Q2 2023, an estimated $14.8M increase.
- Logos Global Management's biggest Q2 2023 reduction was IDEAYA Biosciences, cutting an estimated $38M.
- Logos Global Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $37M.
- Logos Global Management's ten largest holdings make up 51% of its $735M portfolio in Q2 2023.
- Logos Global Management opened 18 new positions and closed 10 in Q2 2023.
- Logos Global Management's portfolio value rose 5.2% quarter-over-quarter to $735M.
Based on Logos Global Management's 13F filing for Q2 2023, filed 14 Aug 2023.